Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
Many Patients With Statin Intolerance Self-Medicate, Despite No Link to Lowering LDL-C
August 29th 2025Self-medication, including the use of dietary supplements and pain relief drugs, were reported by many patients with statin-associated muscle symptoms to lower their low-density lipoprotein cholesterol (LDL-C).
Read More
Neighborhood Marginalization Worsens Outcomes in Young Myocardial Infarction Survivors
August 27th 2025Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events and reduced visits to their physician or cardiologist.
Read More
Expert: How Walgreens Pharmacists Are Tackling Vaccine Hesitancy, Expanding Coadministration
August 22nd 2025Samantha Picking, PharmD, senior director of immunizations at Walgreens, shares how pharmacy teams are addressing vaccine misinformation, managing coadministration, and supporting test-to-treat services during a complex respiratory season.
Read More
Walgreens Enhances Staffing, Operations to Meet 2025 Influenza Vaccine Demand
August 20th 2025Samantha Picking, PharmD, senior director of immunizations at Walgreens, discusses staffing strategies, digital tools, and operational improvements designed to streamline flu vaccination services during the upcoming respiratory season.
Read More
Severe Childhood COVID-19 Associated With Heightened Cardiovascular Risk in Adulthood
August 20th 2025The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.
Read More
Novel Prescription Digital Therapeutic Improves Negative Symptoms of Schizophrenia
August 15th 2025CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.
Read More
Large Burden of Community-Acquired Pneumonia Hospitalizations Among Older US Adults
August 8th 2025Older adults in the United States continue to be burdened with disproportionate rates of community-acquired pneumonia hospitalizations, including due to serotypes covered in the recently approved V116 vaccine.
Read More